The mechanism of action of tacrolimus in atopic dermatitis is not fully understood. Whilethe following have been observed, the clinical significance of these observations in atopicdermatitis is not known. Via its binding to a specific cytoplasmic immunophilin (FKBP12),tacrolimus inhibits calcium-dependent signal transduction pathways in T cells, therebypreventing the transcription and synthesis of IL-2, IL-3, IL-4, IL-5 and other cytokines such asGM-CSF, TNF-α and IFN-γ. In patients with atopic dermatitis, improvement of skin lesionsduring treatment with tacrolimus ointment was associated with reduced Fc receptorexpression on Langerhans cells and a reduction of their hyperstimulatory activity towards Tcells. Tacrolimus ointment does not affect collagen synthesis in humans.
Protopic 0.1 % ointment is indicated in adults and adolescents (16 years of age and above) Protopic 0.03% ointment is indicated over 2 years
Cream with pimecrolimus, a lipophilic anti-inflammatory ascomycin macrolactam derivative and a cell selective inhibitor of the production and release of pro-inflammatory cytokines. Its skin-selective pharmacological profile is different to that of corticosteroids.
The formula of Eucerin AtoControl Acute Care Cream is a skin-calming complex based on four key ingredients: Omega-6 Fatty Acids, Decandiol, Licochalcone A and Menthoxypropanediol. Irritated and reddened skin is calmed and soothed, helping to improve mild to moderate flare-ups significantly.